Boehringer Ingelheim announced that Ofev (nintedanib) capsules are now available for the treatment of idiopathic pulmonary fibrosis (IPF). Ofev is the only kinase inhibitor that is FDA-approved to treat IPF.
Nintedanib is a small molecule that inhibits multiple receptor tyrosine kinases (RTKs) and non-receptor tyrosine kinases (nRTKs). Nintedanib inhibits the following RTKs: platelet-derived growth factor receptor (PDGFR) α and β, fibroblast growth factor receptor (FGFR) 1-3, vascular endothelial growth factor receptor (VEGFR) 1-3, and Fms-like tyrosine kinase-3 (FLT3). Among them, FGFR, PDGFR, and VEGFR have been implicated in IPF pathogenesis.
Nintedanib competitively binds to the ATP binding pocket of these receptors and blocks the intracellular signaling which is crucial for the proliferation, migration, and transformation of fibroblasts representing essential mechanisms of the IPF pathology.
RELATED: Two New Drugs for Idiopathic Pulmonary Fibrosis Approved
Ofev is supplied in 100mg and 150mg capsules in 60-count bottles. Ofev is available through specialty pharmacy distributors and a select network of pharmacies.
For more information call (800) 542-6257 or visit Ofev.com.